Serodiagnosis_NN of_IN Mice_NP Minute_NP Virus_NP and_CC Mouse_NP Parvovirus_NP Infections_NNS in_IN Mice_NNS by_IN Enzyme-Linked_NP Immunosorbent_NP Assay_NP with_IN Baculovirus-Expressed_NP Recombinant_NP VP2_NP Proteins_NPS Mice_NP minute_NN virus_NN (_( MMV_NP )_) and_CC mouse_NN parvovirus_NN (_( MPV_NP )_) type_NN 1_CD are_VBP the_DT two_CD parvoviruses_NNS known_VBN to_TO naturally_RB infect_VB laboratory_NN mice_NNS and_CC are_VBP among_IN the_DT most_RBS prevalent_JJ infectious_JJ agents_NNS found_VBN in_IN contemporary_JJ laboratory_NN mouse_NN colonies_NNS ._SENT Serologic_JJ assays_NNS are_VBP commonly_RB used_VBN to_TO diagnose_VB MMV_NP and_CC MPV_NP infections_NNS in_IN laboratory_NN mice_NNS ;_: however_RB ,_, highly_RB accurate_JJ ,_, high-throughput_JJ serologic_JJ assays_NNS for_IN the_DT detection_NN of_IN MMV-_NP and_CC MPV-infected_JJ mice_NNS are_VBP needed_VBN ._SENT To_TO this_DT end_NN ,_, the_DT major_JJ capsid_NN viral_JJ protein_NN (_( VP2_NP )_) genes_NNS of_IN MMV_NP and_CC MPV_NP were_VBD cloned_VBN and_CC MMV_NP recombinant_JJ VP2_NP (_( rVP2_NN )_) and_CC MPV_NP rVP2_NN proteins_NNS were_VBD expressed_VBN by_IN using_VBG a_DT baculovirus_NN system_NN ._SENT MMV_NP rVP2_NP and_CC MPV_NP rVP2_NP spontaneously_RB formed_VBD virus-like_JJ particles_NNS that_WDT were_VBD morphologically_RB similar_JJ to_TO empty_VB parvovirus_NN capsids_NNS ._SENT These_DT proteins_NNS were_VBD used_VBN as_IN antigens_NNS in_IN enzyme-linked_JJ immunosorbent_JJ assays_NNS (_( ELISAs_NP )_) to_TO detect_VB anti-MMV_NP or_CC anti-MPV_NP antibodies_NNS in_IN the_DT sera_NN of_IN infected_JJ mice_NNS ._SENT Sera_NN from_IN mice_NNS experimentally_RB infected_VBN with_IN MMV_NP (_( n_NN =_SYM 43_CD )_) or_CC MPV_NP (_( n_NN =_SYM 35_CD )_) and_CC sera_NN from_IN uninfected_JJ mice_NNS (_( n_NN =_SYM 30_CD )_) were_VBD used_VBN to_TO evaluate_VB the_DT ELISAs_NP ._SENT The_DT MMV_NP ELISA_NP was_VBD 100_CD %_NN sensitive_JJ and_CC 100_CD %_NN specific_JJ in_IN detecting_VBG MMV-infected_JJ mice_NNS ,_, and_CC the_DT MPV_NP ELISA_NP was_VBD 100_CD %_NN sensitive_JJ and_CC 98.6_CD %_NN specific_JJ in_IN detecting_VBG MPV-infected_JJ mice_NNS ._SENT Both_DT assays_NNS outperformed_VBD a_DT parvovirus_NN ELISA_NN that_WDT uses_VBZ a_DT recombinant_JJ nonstructural_JJ protein_NN (_( NS1_NP )_) of_IN MMV_NP as_IN antigen_NN ._SENT The_DT MMV_NP rVP2_NN and_CC MPV_NN rVP2_NN proteins_NNS provide_VBP a_DT ready_JJ source_NN of_IN easily_RB produced_VBN antigen_NN ,_, and_CC the_DT ELISAs_NP developed_VBD provide_VB highly_RB accurate_JJ ,_, high-throughput_JJ assays_NNS for_IN the_DT serodiagnosis_NN of_IN MMV_NP and_CC MPV_NP infections_NNS in_IN laboratory_NN mice_NNS ._SENT Mice_NNS minute_JJ virus_NN (_( MMV_NP )_) (_( formerly_RB minute_JJ virus_NN of_IN mice_NNS )_) and_CC mouse_NN parvovirus_NN (_( MPV_NP )_) type_NN 1_CD are_VBP among_IN the_DT most_RBS prevalent_JJ infectious_JJ agents_NNS found_VBN in_IN contemporary_JJ laboratory_NN mouse_NN colonies_NNS ._SENT Although_IN the_DT immunosuppressive_JJ strain_NN of_IN MMV_NP (_( MMVi_NP )_) can_MD induce_VB a_DT potentially_RB lethal_JJ renal_JJ hemorrhagic_JJ disease_NN when_WRB experimentally_RB inoculated_VBN into_IN neonatal_JJ mice_NNS ,_, clinical_JJ disease_NN and_CC histologic_JJ lesions_NNS have_VBP not_RB been_VBN reported_VBN for_IN mice_NNS naturally_RB infected_VBN with_IN MMV_NP ._SENT Similarly_RB ,_, clinical_JJ disease_NN and_CC histologic_JJ lesions_NNS have_VBP not_RB been_VBN observed_VBN in_IN mice_NNS naturally_RB or_CC experimentally_RB infected_VBN with_IN MPV_NP ._SENT Despite_IN the_DT absence_NN of_IN clinical_JJ disease_NN and_CC histopathology_NN ,_, murine_JJ parvoviruses_NNS can_MD have_VB significant_JJ deleterious_JJ effects_NNS on_IN research_NN due_JJ to_TO their_PP$ immunomodulatory_JJ effects_NNS both_CC in_IN vivo_JJ and_CC in_IN vitro_NN (_( ,_, ,_, -_: )_) ._SENT In_IN addition_NN ,_, there_EX is_VBZ significant_JJ potential_NN for_IN MMV_NP and_CC MPV_NP to_TO be_VB transmitted_VBN among_IN animals_NNS within_IN a_DT facility_NN due_JJ to_TO the_DT high_JJ degree_NN of_IN environmental_JJ stability_NN of_IN these_DT agents_NNS ._SENT Therefore_RB ,_, identification_NN of_IN infected_JJ laboratory_NN mice_NNS is_VBZ critical_JJ to_TO minimize_VB the_DT impact_NN of_IN murine_JJ parvovirus_NN infections_NNS on_IN research_NN ._SENT Serologic_JJ evaluation_NN for_IN the_DT presence_NN of_IN antiparvovirus_NN antibodies_NNS has_VBZ typically_RB been_VBN used_VBN to_TO diagnose_VB MMV_NP and_CC MPV_NP infections_NNS in_IN mice_NNS ,_, although_IN the_DT type_NN of_IN immunoassay_NN and_CC the_DT source_NN of_IN diagnostic_JJ antigen_NN vary_VBP significantly_RB among_IN rodent_NN diagnostic_JJ laboratories_NNS ._SENT The_DT most_RBS common_JJ methods_NNS used_VBN for_IN the_DT diagnosis_NN parvovirus_NN infections_NNS in_IN mice_NNS include_VBP the_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) ,_, the_DT indirect_JJ fluorescent-antibody_NN assay_NN (_( IFA_NP )_) ,_, and_CC the_DT hemagglutination_NN inhibition_NN (_( HAI_NP )_) assay_NN ,_, with_IN the_DT ELISA_NN being_VBG preferred_VBN due_RB to_TO its_PP$ high-throughput_NN capability_NN ._SENT More_RBR important_JJ than_IN methodology_NN is_VBZ the_DT choice_NN of_IN parvovirus_NN antigen_NN ._SENT MMV_NP antigens_NNS have_VBP been_VBN generated_VBN from_IN cell_NN lines_NNS experimentally_RB infected_VBN with_IN the_DT prototype_NN strain_NN of_IN MMV_NP (_( MMVp_NP )_) ,_, which_WDT grows_VBZ very_RB well_RB in_IN vitro_NN ,_, yielding_VBG highly_RB concentrated_JJ preparations_NNS of_IN MMV_NP antigen_NN ._SENT This_DT antigen_NN works_VBZ well_RB for_IN the_DT detection_NN of_IN MMV_NP infections_NNS in_IN mice_NNS by_IN the_DT ELISA_NP ,_, IFA_NP ,_, and_CC HAI_NP assay_NN formats_NNS ,_, but_CC MMVp_NP antigen_NN also_RB displays_VBZ some_DT cross-reactivity_NN with_IN antibodies_NNS directed_VBN against_IN MPV_NP ._SENT This_DT cross-reactivity_NN is_VBZ primarily_RB the_DT result_NN of_IN antibodies_NNS generated_VBN to_TO the_DT nonstructural_JJ (_( NS_NP )_) proteins_NNS of_IN MPV_NP binding_VBG to_TO the_DT NS_NP proteins_NNS of_IN MMVp_NP in_IN the_DT antigen_NN preparation_NN ,_, reflecting_VBG the_DT high_JJ degree_NN of_IN homology_NN among_IN the_DT NS_NP proteins_NNS of_IN the_DT rodent_NN parvoviruses_NNS ._SENT Cell_NN culture-propagated_VBD MPV_NP can_MD be_VB used_VBN as_IN antigen_NN to_TO detect_VB anti-MPV_NP antibodies_NNS ._SENT However_RB ,_, high-titer_NN stocks_NNS of_IN MPV_NN are_VBP extremely_RB difficult_JJ and_CC expensive_JJ to_TO obtain_VB via_IN cell_NN culture_NN propagation_NN ,_, and_CC this_DT has_VBZ largely_RB precluded_VBN the_DT use_NN of_IN MPV_NN antigens_NNS in_IN ELISAs_NP ._SENT For_IN the_DT past_JJ few_JJ years_NNS ,_, a_DT recombinant_JJ nonstructural_JJ protein_NN of_IN MMV_NP (_( rNS1_JJ )_) ,_, which_WDT is_VBZ highly_RB conserved_VBN among_IN rodent_NN parvoviruses_NNS ,_, has_VBZ been_VBN used_VBN as_IN antigen_NN in_IN serologic_JJ ELISAs_NNS to_TO detect_VB MMV_NP and_CC MPV_NP infections_NNS ._SENT However_RB ,_, recent_JJ findings_NNS indicate_VBP that_IN this_DT assay_NN lacks_VBZ sensitivity_NN in_IN detecting_VBG infections_NNS ,_, particularly_RB MPV_NN infections_NNS ._SENT Thus_RB ,_, serodiagnostic_JJ assays_NNS for_IN MMV_NP and_CC MPV_NP that_WDT use_VBP capsid_NN proteins_NNS as_IN antigens_NNS are_VBP needed_VBN ._SENT The_DT goals_NNS of_IN this_DT study_NN were_VBD to_TO develop_VB sensitive_JJ and_CC specific_JJ recombinant_JJ antigen-based_JJ ELISAs_NNS to_TO detect_VB parvovirus-infected_JJ mice_NNS ._SENT Here_RB we_PP report_VBP on_IN the_DT cloning_VBG of_IN the_DT genes_NNS that_WDT encode_VBP the_DT major_JJ capsid_NN proteins_NNS (_( VP2_NP )_) of_IN MMV_NP and_CC MPV_NP ,_, the_DT expression_NN of_IN recombinant_JJ VP2_NP (_( rVP2_NN )_) of_IN MMV_NP and_CC MPV_NP with_IN baculovirus_NN vectors_NNS ,_, and_CC the_DT use_NN of_IN these_DT recombinant_JJ proteins_NNS as_IN antigens_NNS in_IN ELISAs_NP to_TO detect_VB anti-MMV_NP or_CC anti-MPV_NP antibodies_NNS in_IN sera_NN from_IN experimentally_RB infected_JJ mice_NNS ._SENT Our_PP$ results_NNS show_VBP that_IN the_DT newly_RB developed_VBN ELISAs_NNS are_VBP highly_RB sensitive_JJ and_CC specific_JJ for_IN detecting_VBG parvovirus_NN infections_NNS in_IN mice_NNS ._SENT Viruses_NNS ._SENT |_SYM MPV-1b_NP was_VBD propagated_VBN in_IN CTLL-2_NP murine_JJ cytotoxic_JJ T_NN cells_NNS as_RB described_VBD previously_RB ._SENT MMVi_NP was_VBD a_DT kind_NN gift_NN from_IN Dave_NP Pintel_NP of_IN the_DT University_NP of_IN Missouri_NP ._SENT Construction_NN of_IN recombinant_JJ baculoviruses_NNS ._SENT |_SYM Standard_NP molecular_JJ biology_NN techniques_NNS were_VBD performed_VBN as_IN described_VBN previously_RB ._SENT The_DT MMV_NP VP2_NP and_CC MPV_NP VP2_NP genes_NNS were_VBD amplified_VBN by_IN PCR_NP ._SENT The_DT MMV_NP VP2_NP gene_NN was_VBD amplified_VBN with_IN platinum_NN Pfx_NP DNA_NP polymerase_NN (_( Invitrogen_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) according_VBG to_TO the_DT protocol_NN of_IN the_DT manufacturer_NN ._SENT Each_DT 50-mul_NP reaction_NN mixture_NN contained_VBD 1.25_CD U_NN of_IN polymerase_NN ,_, 290_CD ng_NNS of_IN MMVp_NP pML-n_NP plasmid_NP (_( an_DT MMVp_NP clone_NN that_WDT was_VBD a_DT kind_NN gift_NN from_IN Dave_NP Pintel_NP ,_, University_NP of_IN Missouri_NP )_) as_IN template_NN ,_, and_CC primers_NNS MMV_NP VP2_NP 2664-2682_CD forward_NN (_( 5'-gcggatccgtcgacATGAGTGATGGCACCAGCC-3_NP '_POS )_) and_CC MMV_NP VP2_NP 4436-4413_CD reverse_NN (_( 5'-gcggtaccgcggccgcTTAGTAAGTATTTCTAGCAACAGG-3_NP '_POS )_) ._SENT The_DT uppercase_JJ letters_NNS of_IN the_DT primers_NNS correspond_VBP to_TO MMV_NP genome_NN sequences_NNS ,_, while_IN the_DT lowercase_JJ letters_NNS of_IN the_DT forward_JJ primer_NN represent_VBP engineered_JJ restriction_NN endonuclease_NN sites_NNS for_IN BamHI_NP and_CC SalI_NP and_CC the_DT lowercase_JJ letters_NNS of_IN the_DT reverse_JJ primer_NN represent_VBP engineered_JJ restriction_NN endonuclease_NN sites_NNS for_IN KpnI_NP and_CC NotI_NP ._SENT Thermocycling_NP parameters_NNS consisted_VBD of_IN an_DT initial_JJ denaturation_NN step_NN (_( 94C_NP ,_, 2_CD min_NN )_) ,_, followed_VBN by_IN 35_CD cycles_NNS of_IN denaturation_NN (_( 94C_NP ,_, 15_CD s_NNS )_) ,_, annealing_VBG (_( 55C_NP ,_, 30_CD s_NNS )_) ,_, and_CC extension_NN (_( 68C_NP ,_, 2_CD min_NN )_) ._SENT The_DT MPV_NP VP2_NP gene_NN was_VBD amplified_VBN by_IN a_DT nested_VBN PCR_NP strategy_NN ._SENT A_DT region_NN of_IN the_DT MPV_NP genome_NN was_VBD amplified_VBN with_IN platinum_NN Pfx_NP DNA_NP polymerase_NN (_( Invitrogen_NP )_) according_VBG to_TO the_DT protocol_NN of_IN the_DT manufacturer_NN with_IN the_DT primers_NNS MPV_NN 2634-2653_CD forward_NN (_( 5'-GCACAGCAAAGAACTCAGAC-3_NP '_POS )_) and_CC MPV_NP 4440-4419_CD reverse_NN (_( 5'-CAGAAAGAAAGAACATGGTTGG-3_NP '_POS )_) and_CC an_DT annealing_VBG temperature_NN of_IN 55C_NP ._SENT Each_DT 50-mul_NP reaction_NN mixture_NN contained_VBD 1.25_CD U_NN of_IN polymerase_NN and_CC 370_CD ng_NNS of_IN template_NN DNA_NN from_IN MPV-infected_NP CTLL-2_NP murine_JJ cytotoxic_JJ T_NN cells_NNS that_WDT was_VBD purified_VBN by_IN the_DT DNeasy_NP (_( Qiagen_NP Inc._NP ,_, Valencia_NP ,_, Calif._NP )_) protocol_NN ._SENT An_DT aliquot_JJ (_( 0.5_CD mul_NN )_) of_IN the_DT amplification_NN product_NN from_IN the_DT first_JJ PCR_NP was_VBD used_VBN as_IN template_NN to_TO amplify_VB the_DT MPV_NP VP2_NP gene_NN by_IN using_VBG the_DT Expand_NP High_NP Fidelity_NP PCR_NP system_NN (_( Roche_NP ,_, Indianapolis_NP ,_, Ind._NP )_) and_CC internal_JJ primers_NNS MPV_NN VP2_NP 2664-2682_CD forward_NN (_( 5'-gcgaattcggatccgcATGAGTGATGGCGCCGAGC-3_NP '_POS )_) and_CC MMV_NP VP2_NP 4436-4413_CD reverse_NN (_( see_VB above_IN )_) with_IN an_DT annealing_VBG temperature_NN of_IN 55C_NP ._SENT The_DT uppercase_JJ letters_NNS of_IN the_DT primers_NNS correspond_VBP to_TO regions_NNS of_IN the_DT MPV_NP genome_NN ,_, and_CC the_DT lowercase_JJ letters_NNS of_IN the_DT forward_JJ primer_NN represent_VBP engineered_JJ restriction_NN endonuclease_NN sites_NNS for_IN EcoRI_NP and_CC BamHI_NP ._SENT The_DT amplified_VBN MMV_NP VP2_NP and_CC MPV_NP VP2_NP genes_NNS were_VBD electrophoresed_VBN for_IN 1_CD h_NN at_IN 80_CD V_CD on_IN a_DT 1_CD %_NN SeaPlaque_NP GTG_NP agarose_NN gel_NN (_( FMC_NP BioProducts_NP ,_, Rockland_NP ,_, Maine_NP )_) that_WDT contained_VBD 0.5_CD %_NN ethidium_NN bromide_NN ._SENT Amplicons_NNS were_VBD visualized_VBN under_IN UV_NP light_NN ,_, excised_VBN from_IN the_DT gel_NN ,_, and_CC purified_VBD with_IN the_DT Zymoclean_NP Gel_NP DNA_NP recovery_NN kit_NN (_( Zymo_NP Research_NP ,_, Orange_NP ,_, Calif._NP )_) ;_: and_CC DNA_NN concentrations_NNS were_VBD determined_VBN by_IN measuring_VBG the_DT A260_NP with_IN a_DT spectrophotometer_NN (_( Gene_NP Quant_NP ;_: Amersham_NP Biosciences_NP Corp._NP ,_, Piscataway_NP ,_, N.J._NP )_) ._SENT The_DT purified_VBN MMV_NP and_CC MPV_NP VP2_NP PCR_NP products_NNS were_VBD digested_VBN with_IN BamHI_NP and_CC NotI_NP ._SENT The_DT MMV_NP VP2_NP gene_NN was_VBD directionally_RB cloned_VBN ,_, in_IN frame_NN ,_, into_IN the_DT His-tagged_JJ fusion_NN vector_NN pFastBac_NN HTb_NP (_( Invitrogen_NP )_) to_TO create_VB the_DT plasmid_NP MMV-VP2-pFastBac_NP HTb_NP ._SENT The_DT MPV_NP VP2_NP PCR_NP product_NN was_VBD directionally_RB cloned_VBN ,_, in_IN frame_NN ,_, into_IN the_DT His-tagged_JJ fusion_NN vector_NN pFastBac_NN HTc_NP (_( Invitrogen_NP )_) to_TO create_VB the_DT plasmid_NP MPV-VP2-pFastBac_NP HTc_NP ._SENT Plasmid_NP MMV-VP2-pFastBac_NP HTb_NP or_CC MPV-VP2-pFastBac_NP HTc_NP was_VBD used_VBN to_TO construct_VB independent_JJ recombinant_JJ baculovirus_NN expression_NN vectors_VBZ MMV-VP2_NP Bac_NP and_CC MPV-VP2_NP Bac_NP ,_, respectively_RB ,_, by_IN using_VBG the_DT Bac-to-Bac_NP Baculovirus_NP expression_NN system_NN (_( Invitrogen_NP )_) ._SENT High-titer_NN stocks_NNS of_IN recombinant_JJ baculoviruses_NNS were_VBD generated_VBN in_IN Spodoptera_NP frugiperda_NP (_( Sf-9_NP )_) insect_NN cells_NNS (_( Invitrogen_NP )_) ,_, and_CC viral_JJ titers_NNS were_VBD determined_VBN by_IN plaque_NN assay_NN ._SENT Production_NN of_IN recombinant_JJ proteins_NNS and_CC purification_NN of_IN ELISA_NP antigens_NNS ._SENT |_SYM Standard_NP insect_NN cell_NN and_CC baculovirus_NN propagation_NN protocols_NNS were_VBD followed_VBN ._SENT Pilot_NN experiments_NNS were_VBD performed_VBN to_TO determine_VB the_DT kinetics_NN for_IN maximal_JJ production_NN of_IN each_DT recombinant_JJ protein_NN ._SENT To_TO generate_VB large_JJ quantities_NNS of_IN MMV_NP rVP2_NP or_CC MPV_NP rVP2_JJ protein_NN for_IN use_NN as_IN antigens_NNS ,_, 1-liter_JJ pendulum_NN spinner_NN flasks_NNS (_( Wheaton_NP Science_NP Products_NP ,_, Millville_NP ,_, N.J._NP )_) were_VBD seeded_VBN with_IN 600_CD ml_NN of_IN High_NP Five_NP insect_NN cells_NNS (_( Invitrogen_NP )_) at_IN a_DT density_NN of_IN 9_CD x_NN 105_CD cells_NNS per_IN ml_NN in_IN complete_JJ insect_NN cell_NN medium_NN (_( Insecta-FIVE_JJ medium_NN ;_: Mediatech_NP ,_, Inc._NP ,_, Herndon_NP ,_, Va._NP )_) supplemented_VBD with_IN 1.36_CD mg_NN of_IN l-glutamine_NN per_IN ml_NN and_CC 5_CD %_NN fetal_JJ bovine_JJ serum_NN ._SENT Cells_NNS were_VBD infected_VBN with_IN recombinant_JJ baculovirus_NN at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 1.0_CD for_IN MMV-VP2_NP Bac_NP or_CC 0.1_CD for_IN MPV-VP2_NP Bac_NP ._SENT At_IN 72_CD h_NN postinoculation_NN the_DT cells_NNS were_VBD pelleted_VBN by_IN centrifugation_NN at_IN 500_CD x_NN g_NN for_IN 15_CD min_NN at_IN 4C_JJ ,_, resuspended_JJ in_IN 50_CD ml_NN of_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) ,_, and_CC disrupted_VBD by_IN six_CD 30-s_JJ cycles_NNS of_IN sonication_NN (_( Sonifer_NP Cell_NP Disrupter_NP 185_CD ;_: Branson_NP Ultrasonics_NP Corp._NP ,_, Danbury_NP ,_, Conn._NP )_) with_IN a_DT cup_NN sonicator_NN (_( Heat_NP Systems_NPS Ultrasonics_NP ,_, Farmingdale_NP ,_, N.Y._NP )_) on_IN ice_NN ._SENT Insoluble_JJ material_NN was_VBD pelleted_VBN by_IN centrifugation_NN at_IN 20,000_CD x_NN g_NN for_IN 1_CD h_NN at_IN 4C_JJ ._SENT The_DT clarified_VBN supernatant_JJ of_IN the_DT MMV_NP rVP2_NN preparation_NN (_( semipurified_JJ protein_NN )_) was_VBD harvested_VBN and_CC used_VBN as_IN antigen_NN in_IN the_DT MMV_NP rVP2_NN ELISA_NP ._SENT Uninfected_JJ High_JJ Five_JJ insect_NN cells_NNS cultivated_VBN and_CC processed_VBN in_IN the_DT same_JJ manner_NN were_VBD used_VBN as_IN controls_NNS in_IN the_DT MMV_NP ELISA_NP ._SENT To_TO further_RBR purify_VB the_DT MPV_NN rVP2_NN for_IN use_NN as_IN antigen_NN in_IN the_DT MPV_NP ELISA_NP and_CC to_TO purify_VB the_DT MMV_NP rVP2_NN and_CC MPV_NN rVP2_NN proteins_NNS for_IN electron_NN microscopy_NN ,_, clarified_VBN supernatants_NNS of_IN vector-infected_JJ insect_NN cells_NNS were_VBD loaded_VBN onto_IN 10_CD to_TO 40_CD %_NN cesium_NN chloride_NN gradients_NNS and_CC centrifuged_VBN at_IN 26,500_CD rpm_NN in_IN an_DT SW48_NP rotor_NN (_( Beckman_NP Coulter_NP ,_, Inc._NP ,_, Fullerton_NP ,_, Calif._NP )_) for_IN 16_CD h_NN at_IN 4C_JJ in_IN an_DT ultracentrifuge_NN (_( Beckman_NP Coulter_NP ,_, Inc._NP )_) ._SENT Following_VBG centrifugation_NN ,_, the_DT area_NN of_IN the_DT gradient_NN containing_VBG the_DT rVP2_JJ proteins_NNS was_VBD visualized_VBN as_IN a_DT blue_JJ band_NN at_IN a_DT density_NN of_IN 1.31_CD g/cm3_NN ._SENT This_DT fraction_NN was_VBD harvested_VBN ,_, and_CC the_DT recovered_VBN proteins_NNS were_VBD dialyzed_VBN overnight_RB at_IN 4C_JJ against_IN PBS_NP through_IN a_DT 10,000-Da-cutoff_NP membrane_NN (_( Pierce_NP Endogen_NP ,_, Rockford_NP ,_, Ill._NP )_) ._SENT The_DT concentrations_NNS of_IN the_DT recovered_VBN proteins_NNS were_VBD determined_VBN by_IN a_DT bicinchoninic_JJ acid_NN procedure_NN ,_, and_CC the_DT proteins_NNS were_VBD stored_VBN at_IN -80C_NN until_IN use_NN ._SENT Western_JJ blot_NN analysis_NN ._SENT |_SYM Proteins_NPS were_VBD separated_VBN by_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN (_( SDS-PAGE_NP )_) and_CC transferred_VBN to_TO Immobilon-P_NP transfer_NN membranes_NNS (_( Millipore_NP ,_, Bedford_NP ,_, Mass._NP )_) ._SENT Molecular_JJ weight_NN markers_NNS were_VBD included_VBN on_IN each_DT gel_NN to_TO facilitate_VB the_DT calculation_NN of_IN the_DT sizes_NNS of_IN the_DT protein_NN bands_NNS ._SENT Membranes_NNS were_VBD blocked_VBN with_IN 5_CD %_NN nonfat_NN dry_JJ milk_NN in_IN PBS_NP (_( 1.4_CD mM_NP NaH2PO4_NP ,_, 10.8_CD mM_NP Na2HPO4_NP ,_, 137.9_CD mM_NP NaCl_NP [_SYM pH_NN 7.4_CD ]_SYM )_) and_CC probed_VBN with_IN diluted_JJ sera_NN (_( 1:200_CD )_) from_IN mice_NNS experimentally_RB infected_VBN with_IN MMV_NP ,_, mice_NNS naturally_RB infected_VBN with_IN MPV_NP ,_, or_CC parvovirus-free_JJ mice_NNS ._SENT The_DT membranes_NNS were_VBD incubated_VBN sequentially_RB in_IN solutions_NNS of_IN biotinylated_JJ goat_NN anti-mouse_NN antibody_NN diluted_VBN 1:1,000_NP (_( Jackson_NP Immunoresearch_NP Laboratories_NPS ,_, Inc._NP ,_, West_NP Grove_NP ,_, Pa._NP )_) and_CC avidin_NN DH_NP (_( Vector_NP Laboratories_NP ,_, Inc._NP )_) and_CC were_VBD developed_VBN with_IN peroxidase_NN substrate_NN solution_NN (_( Kirkegaard_NP &_CC Perry_NP ,_, Gaithersburg_NP ,_, Md._NP )_) ._SENT Parvovirus_NN serology_NN ._SENT |_SYM For_IN the_DT MMV_NP ELISA_NP ,_, semipurified_JJ MMV_NP rVP2_NN protein_NN was_VBD diluted_VBN to_TO 1.0_CD mug/ml_NN in_IN coating_NN buffer_NN (_( 0.1_CD M_NP NaHCO3_NP [_SYM pH_NN 9.6_CD ]_SYM )_) and_CC insect_NN cell_NN control_NN protein_NN was_VBD diluted_VBN to_TO 0.5_CD mug/ml_NN in_IN coating_NN buffer_NN ;_: 200_CD mul_NN of_IN each_DT was_VBD coated_VBN onto_IN separate_JJ wells_NNS of_IN an_DT Immulon_NP 2_CD 96-well_NN plate_NN (_( Dynex_NP Technologies_NP ,_, Inc._NP ,_, Chantilly_JJ ,_, Va_NP )_) ._SENT For_IN the_DT MPV_NP ELISA_NP ,_, CsCl-purified_NP MPV_NP rVP2_JJ protein_NN was_VBD diluted_VBN to_TO 0.1_CD mug/ml_NN in_IN coating_NN buffer_NN ,_, and_CC 200_CD mul_NN was_VBD loaded_VBN into_IN test_NN wells_NNS of_IN an_DT Immulon_NP 2_CD 96-well_NN plate_NN ._SENT Control_NN wells_NNS were_VBD uncoated_JJ ._SENT Proteins_NNS were_VBD allowed_VBN to_TO bind_VB to_TO the_DT plates_NNS for_IN 48_CD h_NN at_IN 4C_JJ ._SENT The_DT wells_NNS were_VBD emptied_VBN and_CC washed_VBN three_CD times_NNS in_IN PBS_NP with_IN 0.05_CD %_NN Tween_NP 20_CD (_( PBS-Tween_NP )_) ._SENT Blocking_VBG buffer_NN (_( PBS_NP with_IN 0.5_CD %_NN nonfat_NN dry_JJ milk_NN and_CC 0.05_CD %_NN Tween_NP 20_CD )_) (_( 300_CD mul_NN )_) was_VBD added_VBN to_TO each_DT well_NN ,_, the_DT mixture_NN was_VBD incubated_VBN for_IN 30_CD min_NN at_IN room_NN temperature_NN ,_, and_CC the_DT buffer_NN was_VBD discarded_VBN ;_: 200_CD mul_NN of_IN serum_NN diluted_VBN 1:100_CD in_IN blocking_VBG buffer_NN was_VBD added_VBN to_TO experimental_JJ and_CC control_NN wells_NNS ._SENT After_IN incubation_NN at_IN 37C_JJ for_IN 2_CD h_NN ,_, the_DT plates_NNS were_VBD washed_VBN three_CD times_NNS in_IN PBS-Tween_NP ._SENT Two_CD hundred_CD microliters_NNS of_IN alkaline_JJ phosphatase-labeled_JJ secondary_JJ antibody_NN [_SYM F(ab')2_JJ fragment_NN goat_NN anti-mouse_NN immunoglobulin_NN G_NP (_( heavy_JJ and_CC light_JJ chains_NNS )_) ;_: Jackson_NP Immunoresearch_NP Laboratories_NPS ,_, Inc._NP ]_SYM )_) diluted_VBD 1:7,000_CD in_IN PBS-Tween_NP was_VBD added_VBN to_TO each_DT well_NN ,_, and_CC the_DT plate_NN was_VBD incubated_VBN at_IN 37C_JJ for_IN 2_CD h._NN The_DT plates_NNS were_VBD washed_VBN five_CD times_NNS in_IN PBS-Tween_NP ._SENT One_CD hundred_CD microliters_NNS of_IN phosphatase_NN substrate_NN solution_NN (_( 1_CD mg_NN of_IN Sigma_NP 104_CD phosphatase_NN substrate_NN [_SYM Sigma_NP Chemical_NP Company_NP ,_, St._NP Louis_NP ,_, Mo._NP ]_SYM per_IN 1_CD ml_NN of_IN substrate_NN buffer_NN [_SYM 2_CD mM_NP MgCl2_NP ,_, 27.5_CD mM_NP NaCO3_NP ,_, 22.5_CD mM_NP NaHCO3_NP {_( pH_NN 9.8_CD }_) ]_SYM )_) was_VBD added_VBN to_TO each_DT well_NN ,_, and_CC the_DT plate_NN was_VBD incubated_VBN in_IN the_DT dark_NN at_IN room_NN temperature_NN for_IN 45_CD min_NN ._SENT The_DT optical_JJ density_NN (_( OD_NN )_) of_IN each_DT well_NN was_VBD measured_VBN (_( Kinetic_NP Reader_NP EL312E_NP ;_: Bio-Tek_NP Instruments_NPS ,_, Inc._NP ,_, Winooski_NP ,_, Vt._NP )_) and_CC automatically_RB calculated_VBN as_IN the_DT OD_NN at_IN 405_CD nm_NN (_( OD405_NP )_) minus_CC the_DT OD490_NP to_TO correct_VB for_IN optical_JJ interference_NN ._SENT For_IN each_DT serum_NN sample_NN ,_, the_DT final_JJ OD_NN was_VBD calculated_VBN as_IN the_DT OD_NN of_IN the_DT test_NN well_RB minus_IN the_DT OD_NN of_IN the_DT control_NN well_RB ._SENT The_DT cutoff_NN OD_NN value_NN for_IN each_DT ELISA_NP was_VBD set_VBN at_IN 3_CD standard_JJ deviations_NNS above_IN the_DT mean_NN for_IN 30_CD serum_NN samples_NNS from_IN mice_NNS negative_JJ for_IN parvovirus_NN infections_NNS ._SENT The_DT MMV_NP rVP2_NN ELISA_NP and_CC the_DT MPV_NP rVP2_NP ELISA_NP were_VBD compared_VBN to_TO a_DT parvovirus_NN ELISA_NN that_WDT uses_VBZ a_DT recombinant_JJ nonstructural_JJ protein_NN (_( rNS1_JJ )_) of_IN MMV_NP as_IN antigen_NN ._SENT The_DT rNS1_JJ ELISA_NP was_VBD performed_VBN as_IN described_VBN previously_RB ._SENT Performance_NN of_IN ELISAs_NP ._SENT |_SYM The_DT following_VBG were_VBD calculated_VBN for_IN each_DT ELISA_NP :_: sensitivity_NN =_SYM TP/(TP_NP +_SYM FN_NP )_) x_SYM 100_CD ,_, specificity_NN =_SYM TN/(TN_NP +_SYM FP_NP )_) x_SYM 100_CD ,_, positive_JJ predictive_JJ value_NN =_SYM TP/(TP_NP +_SYM FP_NP )_) x_SYM 100_CD ,_, negative_JJ predictive_JJ value_NN =_SYM TN/(TN_NP +_SYM FN_NP )_) x_SYM 100_CD ,_, and_CC accuracy_NN =_SYM (_( TP_NP +_SYM TN)/(TP_NP +_SYM FP_NP +_SYM TN_NP +_SYM FN_NP )_) ,_, where_WRB TP_NP is_VBZ the_DT number_NN of_IN samples_NNS with_IN true-positive_JJ results_NNS ,_, TN_NP is_VBZ the_DT number_NN of_IN samples_NNS with_IN true-negative_JJ results_NNS ,_, FP_NP is_VBZ the_DT number_NN of_IN samples_NNS with_IN false-positive_JJ results_NNS ,_, and_CC FN_NP is_VBZ the_DT number_NN of_IN samples_NNS with_IN false-negative_JJ results_NNS ._SENT For_IN each_DT ELISA_NP ,_, a_DT Kruskal-Wallis_NP one-way_JJ analysis_NN of_IN variance_NN on_IN ranks_NNS was_VBD performed_VBN to_TO test_VB for_IN differences_NNS between_IN groups_NNS of_IN mice_NNS ._SENT Statistical_JJ significance_NN was_VBD set_VBN at_IN a_DT P_NN value_NN of_IN <=0.01_NN ._SENT Mice_NNS ,_, experimental_JJ infections_NNS ,_, and_CC sera_NN ._SENT |_SYM Four-_NP ,_, 8-_CD ,_, and_CC 12-week-old_JJ male_JJ Hsd:ICR(CD-1)_NP mice_NNS and_CC 12-week-old_JJ male_JJ BALB/cAnNHsd_NN ,_, C3H/HeNHsd_NP ,_, C57BL/6NHsd_NP ,_, and_CC DBA/2NHsd_NN mice_NNS were_VBD obtained_VBN (_( Harlan_NP Sprague-Dawley_NP ,_, Inc._NP ,_, Indianapolis_NP ,_, Ind._NP )_) ._SENT The_DT mice_NNS were_VBD separated_VBN into_IN experimental_JJ and_CC control_NN groups_NNS of_IN three_CD to_TO five_CD animals_NNS each_DT according_VBG to_TO strain_VB ,_, age_NN ,_, and_CC dose_NN of_IN viral_JJ inoculum_NN ._SENT Mice_NNS were_VBD inoculated_VBN with_IN 5_CD x_NN 104_CD to_TO 1_CD x_SYM 106_CD 50_CD %_NN tissue_NN culture_NN infective_JJ doses_NNS of_IN MPV-1b_NP diluted_VBN in_IN TE_NNS (_( 50_CD mM_NP Tris_NP base_NN ,_, 10_CD mM_NP EDTA_NP [_SYM pH_NN 8.7_CD ]_SYM )_) or_CC with_IN TE_NN by_IN intragastric_JJ gavage_NN under_IN isofluorane_NN anesthesia_NN ._SENT At_IN 4_CD weeks_NNS postinoculation_NN ,_, the_DT mice_NNS were_VBD euthanized_JJ with_IN an_DT inhaled_VBN overdose_NN of_IN carbon_NN dioxide_NN ,_, blood_NN was_VBD collected_VBN by_IN cardiocentesis_NN ,_, and_CC the_DT sera_NN were_VBD collected_VBN ._SENT For_IN the_DT MMV_NP experimental_JJ infections_NNS ,_, pregnant_JJ female_JJ C3H/HeNHsd_NN mice_NNS were_VBD obtained_VBN (_( Harlan_NP Sprague-Dawley_NP )_) ,_, and_CC neonatal_JJ male_JJ and_CC female_JJ pups_NNS were_VBD inoculated_VBN oronasally_RB with_IN 5_CD x_SYM 104_CD 50_CD %_NN tissue_NN culture_NN infective_JJ doses_NNS of_IN MMVi_NP ._SENT Mice_NNS were_VBD euthanized_JJ with_IN an_DT inhaled_VBN overdose_NN of_IN carbon_NN dioxide_NN at_IN 8_CD weeks_NNS postinoculation_NN ,_, blood_NN was_VBD collected_VBN by_IN cardiocentesis_NN ,_, and_CC the_DT sera_NN were_VBD collected_VBN ._SENT Sera_NN from_IN all_DT mice_NNS were_VBD diluted_VBN 1:5_CD in_IN PBS_NP ,_, heat_NN inactivated_VBD at_IN 56C_NN for_IN 30_CD min_NN ,_, and_CC stored_VBD at_IN -20C_NN until_IN use_NN ._SENT The_DT source_NN colonies_NNS for_IN all_DT mice_NNS were_VBD documented_VBN to_TO be_VB free_JJ of_IN known_VBN mouse_NN pathogens_NNS ,_, including_VBG MPV_NP and_CC MMV_NP ._SENT Each_DT experimental_JJ and_CC control_NN group_NN was_VBD housed_VBN separately_RB in_IN microisolation_NN cages_NNS ,_, and_CC all_DT animal_JJ manipulations_NNS were_VBD performed_VBN in_IN a_DT class_NN II_NP biological_JJ safety_NN cabinet_NN by_IN standard_JJ microisolation_NN technique_NN ._SENT All_DT animal_NN studies_NNS were_VBD approved_VBN by_IN the_DT University_NP of_IN Missouri_NP or_CC the_DT University_NP of_IN Arizona_NP Institutional_NP Animal_NP Care_NP and_CC Use_NP Committee_NP ._SENT Sera_NN from_IN MPV-inoculated_JJ mice_NNS that_WDT were_VBD positive_JJ for_IN anti-MPV_NP antibodies_NNS by_IN an_DT MPV_NP IFA_NP ,_, sera_NN from_IN MMV-inoculated_JJ mice_NNS that_WDT were_VBD positive_JJ for_IN anti-MMV_NP antibodies_NNS by_IN an_DT MMV_NP IFA_NP ,_, and_CC sera_NN from_IN uninfected_JJ mice_NNS were_VBD used_VBN in_IN the_DT ELISAs_NP ._SENT The_DT MMV_NP and_CC MPV_NP IFAs_NP were_VBD performed_VBN as_IN described_VBN previously_RB ._SENT In_IN Western_JJ blot_NN experiments_NNS ,_, sera_NN from_IN MMV-inoculated_JJ mice_NNS that_WDT were_VBD positive_JJ for_IN anti-MMV_NP antibodies_NNS by_IN IFA_NP were_VBD used_VBN as_IN MMV-positive_JJ sera_NN ,_, sera_NN from_IN FVB/NCr_NP mice_NNS that_WDT were_VBD naturally_RB infected_VBN with_IN MPV_NP were_VBD used_VBN as_IN MPV-positive_JJ sera_NN ,_, and_CC sera_NN from_IN uninfected_JJ mice_NNS were_VBD used_VBN as_IN negative_JJ sera_NN ._SENT The_DT mice_NNS naturally_RB infected_VBN with_IN MPV_NP were_VBD positive_JJ for_IN anti-MPV_NP antibodies_NNS by_IN MPV_NP IFA_NP ,_, positive_JJ for_IN MPV_NP DNA_NP by_IN MPV_NP PCR_NP of_IN mesenteric_JJ lymph_NN nodes_NNS ,_, negative_JJ for_IN anti-MMV_NP antibodies_NNS by_IN MMV_NP IFA_NP ,_, and_CC negative_JJ for_IN MMV_NP DNA_NP by_IN PCR_NP of_IN mesenteric_JJ lymph_NN nodes_NNS ._SENT Electron_NP microscopy_NN ._SENT |_SYM The_DT MPV_NP rVP2_NP and_CC MMV_NP rVP2_NN proteins_NNS were_VBD expressed_VBN and_CC purified_VBN by_IN CsCl_NP gradient_JJ centrifugation_NN as_IN described_VBN above_IN ,_, with_IN the_DT exception_NN that_IN the_DT recovered_VBN fractions_NNS were_VBD diluted_VBN in_IN PBS_NP and_CC centrifuged_VBN at_IN 41,000_CD rpm_NN for_IN 5_CD h_NN in_IN an_DT SW_NP 41_CD rotor_NN (_( Beckman_NP )_) at_IN 4C_JJ to_TO pellet_VB the_DT proteins_NNS ._SENT The_DT pellets_NNS of_IN each_DT protein_NN were_VBD resuspended_VBN in_IN 1_CD %_NN ammonium_NN acetate_NN ._SENT A_DT small_JJ droplet_NN of_IN each_DT sample_NN in_IN 4_CD %_NN phosphotungstate_NN was_VBD deposited_VBN on_IN a_DT carbon-coated_JJ grid_NN and_CC examined_VBD with_IN a_DT Hitachi_NP H-6700_NP transmission_NN electron_NN microscope_NN ._SENT MMV_NP rVP2_NP and_CC MPV_NP rVP2_JJ self-assemble_NN into_IN VLPs_NP ._SENT |_SYM The_DT VP2_JJ genes_NNS of_IN MMV_NP and_CC MPV_NP were_VBD cloned_VBN to_TO create_VB the_DT baculovirus_NN vectors_VBZ MMV-rVP2_NP Bac_NP and_CC MPV-rVP2_NP Bac_NP ._SENT These_DT vectors_NNS were_VBD used_VBN to_TO express_VB the_DT recombinant_JJ capsid_NN proteins_VBZ MMV_NP rVP2_NP and_CC MPV_NP rVP2_NN in_IN insect_NN cells_NNS ._SENT It_PP is_VBZ known_VBN that_IN many_JJ parvovirus_NNS recombinant_JJ VP2_NP proteins_NNS ,_, including_VBG MMV_NP rVP2_NN ,_, assemble_VBP into_IN virus-like_JJ particles_NNS (_( VLPs_NP )_) when_WRB expressed_VBN in_IN baculovirus_NN expression_NN systems_NNS ._SENT To_TO determine_VB if_IN baculovirus-expressed_JJ MMV_NP rVP2_NN or_CC MPV_NN rVP2_NN proteins_NNS self-assembled_VBN into_IN VLPs_NP ,_, we_PP subjected_VBD clarified_VBN supernatants_NNS of_IN insect_NN cells_NNS infected_VBN with_IN the_DT MMV-rVP2_NP Bac_NP vector_NN or_CC the_DT MPV-rVP2_NP Bac_NP vector_NN to_TO CsCl_NP gradient_JJ ultracentrifugation_NN ._SENT Each_DT gradient_NN yielded_VBD a_DT visible_JJ blue_JJ band_NN at_IN a_DT density_NN of_IN 1.31_CD g/cm3_NN of_IN CsCl_NP ,_, which_WDT is_VBZ slightly_RB less_RBR dense_JJ than_IN previously_RB reported_VBN densities_NNS of_IN MMV_NP VLPs_NP and_CC empty_JJ parvovirus_NN capsids_NNS (_( 1.32_CD g/cm3_NN of_IN CsCl_NP )_) ._SENT Transmission_NN electron_NN microscopic_JJ examination_NN of_IN negative_JJ stained_VBN preparations_NNS of_IN the_DT collected_VBN bands_NNS revealed_VBD the_DT presence_NN of_IN VLPs_NP morphologically_RB similar_JJ to_TO empty_VB parvovirus_NN capsids_NNS ._SENT The_DT MMV_NP VLPs_NP and_CC MPV_NP VLPs_NP were_VBD isometric_JJ and_CC approximately_RB 20_CD nm_NN in_IN diameter_NN ._SENT Western_JJ blots_NNS of_IN MMV_NP rVP2_NN and_CC MPV_NN rVP2_NN ._SENT |_SYM To_TO determine_VB if_IN MMV_NP rVP2_NP and_CC MPV_NP rVP2_NN reacted_VBD with_IN natural_JJ antibodies_NNS to_TO MMV_NP or_CC MPV_NP and_CC if_IN the_DT recombinant_JJ proteins_NNS shared_VBD cross-reactive_JJ epitopes_NNS ,_, CsCl-purified_NP MMV_NP rVP2_NN and_CC MPV_NN rVP2_NN were_VBD subjected_VBN to_TO SDS-PAGE_NP and_CC Western_NP blot_NN analysis_NN ._SENT The_DT Western_JJ blots_NNS were_VBD probed_VBN with_IN MMV-positive_JJ sera_NN ,_, MPV-positive_JJ sera_NN ,_, or_CC parvovirus-negative_JJ sera_NN ._SENT MMV_NP rVP2_NN was_VBD visualized_VBN as_IN a_DT 68-kDa_JJ immunoreactive_JJ protein_NN band_NN ,_, and_CC MPV_NP rVP2_NN was_VBD visualized_VBN as_IN a_DT 69-kDa_JJ immunoreactive_JJ protein_NN band_NN ._SENT The_DT molecular_JJ masses_NNS of_IN the_DT recombinant_JJ proteins_NNS represent_VBP the_DT molecular_JJ mass_NN of_IN the_DT VP2_NP protein_NN plus_CC the_DT molecular_JJ mass_NN of_IN the_DT leader_NN peptide_NN of_IN the_DT fusion_NN protein_NN ._SENT The_DT MMV_NP rVP2_NN protein_NN reacted_VBD strongly_RB with_IN four_CD of_IN five_CD MMV-positive_JJ serum_NN samples_NNS ,_, reacted_VBD weakly_RB with_IN one_CD of_IN five_CD MMV-positive_JJ serum_NN samples_NNS ,_, and_CC displayed_VBD cross-reactivity_NN with_IN two_CD of_IN five_CD MPV-positive_JJ serum_NN samples_NNS ._SENT The_DT MPV_NP rVP2_NN protein_NN reacted_VBD strongly_RB with_IN all_DT five_CD MPV-positive_JJ serum_NN samples_NNS and_CC cross-reacted_VBD weakly_RB with_IN two_CD of_IN five_CD MMV-positive_JJ serum_NN samples_NNS ._SENT The_DT MMV_NP rVP2_NN and_CC MPV_NN rVP2_NN proteins_NNS did_VBD not_RB react_VB with_IN sera_NN from_IN uninfected_JJ mice_NNS ._SENT In_IN an_DT ELISA_NP format_NN ,_, MMV-positive_JJ sera_NN reacted_VBD only_RB with_IN MMV_NP rVP2_NN ,_, MPV-positive_JJ sera_NN reacted_VBD only_RB with_IN MPV_NN rVP2_NN ,_, and_CC parvovirus-negative_JJ sera_NN did_VBD not_RB react_VB with_IN either_DT antigen_NN ._SENT MMV-_NP and_CC MPV-specific_NP ELISAs_NP ._SENT |_SYM The_DT baculovirus-expressed_JJ MMV_NP rVP2_NN and_CC MPV_NN rVP2_NN proteins_NNS yielded_VBD large_JJ amounts_NNS of_IN readily_RB produced_VBN antigens_NNS to_TO develop_VB the_DT MMV-_NP and_CC MPV-specific_NP ELISAs_NP ._SENT From_IN 600-ml_JJ suspension_NN cultures_NNS of_IN vector-infected_JJ insect_NN cells_NNS ,_, 250_CD mg_NN of_IN semipurified_JJ MMV_NP rVP2_NN antigen_NN or_CC 1.2_CD mg_NN of_IN CsCl_NP gradient-purified_JJ MPV_NN rVP2_NN was_VBD produced_VBN ._SENT The_DT semipurified_JJ preparation_NN of_IN MMV_NP rVP2_NN was_VBD used_VBN as_IN antigen_NN for_IN the_DT MMV_NP ELISA_NP ,_, and_CC the_DT CsCl-purified_NP MPV_NP rVP2_NN was_VBD used_VBN as_IN antigen_NN for_IN the_DT MPV_NP ELISA_NP ._SENT These_DT antigen_NN preparations_NNS were_VBD chosen_VBN on_IN the_DT basis_NN of_IN preliminary_JJ ELISA_NP experiments_NNS that_WDT showed_VBD the_DT marked_JJ immunoreactivity_NN of_IN semipurified_JJ MMV_NP antigen_NN with_IN MMV-positive_JJ sera_NN and_CC the_DT poor_JJ immunoreactivity_NN of_IN semipurified_JJ MPV_NN antigen_NN with_IN MPV-positive_JJ sera_NN ._SENT Strong_JJ immunoreactivity_NN of_IN MPV_NN rVP2_NN in_IN an_DT ELISA_NP was_VBD obtained_VBN only_RB when_WRB CsCl-purified_NP MPV_NP rVP2_NN was_VBD used_VBN as_IN antigen_NN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT baseline_JJ cutoff_NN OD405_NN values_NNS used_VBN to_TO designate_VB positive_JJ sera_NN were_VBD calculated_VBN to_TO be_VB 0.160_CD for_IN the_DT MMV_NP ELISA_NP and_CC 0.093_CD for_IN the_DT MPV_NP ELISA_NP ._SENT To_TO compare_VB the_DT performances_NNS of_IN the_DT MMV_NP ELISA_NP and_CC the_DT MPV_NP ELISA_NP to_TO that_DT of_IN a_DT previously_RB described_VBN generic_JJ parvovirus_NN ELISA_NN that_WDT detects_VBZ anti-NS1_JJ antibodies_NNS ,_, sera_NN from_IN mice_NNS experimentally_RB infected_VBN with_IN MMV_NP or_CC MPV_NP and_CC sera_NN from_IN uninfected_JJ mice_NNS were_VBD tested_VBN by_IN the_DT MMV_NP ELISA_NP ,_, the_DT MPV_NP ELISA_NP ,_, and_CC the_DT rNS1_JJ ELISA_NP ._SENT The_DT MMV_NP ELISA_NP was_VBD 100_CD %_NN sensitive_JJ and_CC 100_CD %_NN specific_JJ in_IN detecting_VBG MMV-infected_JJ mice_NNS and_CC had_VBD a_DT 100_CD %_NN positive_JJ predictive_JJ value_NN ,_, a_DT 100_CD %_NN negative_JJ predictive_JJ value_NN ,_, and_CC an_DT accuracy_NN of_IN 100_CD %_NN ._SENT The_DT MPV_NP ELISA_NP was_VBD 100_CD %_NN sensitive_JJ and_CC 98.6_CD %_NN specific_JJ in_IN detecting_VBG MPV-infected_JJ mice_NNS and_CC had_VBD a_DT 97.2_CD %_NN positive_JJ predictive_JJ value_NN ,_, a_DT 100_CD %_NN negative_JJ predictive_JJ value_NN ,_, and_CC an_DT accuracy_NN of_IN 99_CD %_NN ._SENT The_DT rNS1_JJ ELISA_NP was_VBD 21_CD %_NN sensitive_JJ and_CC 100_CD %_NN specific_JJ in_IN detecting_VBG MPV-infected_JJ mice_NNS ,_, was_VBD 0_CD %_NN sensitive_JJ and_CC 100_CD %_NN specific_JJ in_IN detecting_VBG MMV-infected_JJ mice_NNS ,_, and_CC had_VBD a_DT 100_CD %_NN positive_JJ predictive_JJ value_NN ,_, a_DT 28_CD %_NN negative_JJ predictive_JJ value_NN ,_, and_CC an_DT accuracy_NN of_IN 76_CD %_NN for_IN detecting_VBG mice_NNS infected_VBN with_IN MMV_NP or_CC MPV_NP ._SENT These_DT results_NNS demonstrate_VBP that_IN the_DT MMV_NP ELISA_NP and_CC the_DT MPV_NP ELISA_NP are_VBP sensitive_JJ and_CC specific_JJ and_CC markedly_RB outperform_VB the_DT rNS1_JJ ELISA_NP for_IN detecting_VBG antibodies_NNS to_TO MMV_NP or_CC MPV_NP ._SENT The_DT performances_NNS of_IN the_DT MMV_NP ELISA_NP and_CC the_DT MPV_NP ELISA_NP were_VBD further_RBR characterized_VBN by_IN examining_VBG the_DT intensities_NNS of_IN the_DT OD_JJ values_NNS generated_VBD when_WRB sera_NN from_IN MMV-infected_JJ mice_NNS ,_, MPV-infected_JJ mice_NNS ,_, and_CC parvovirus-negative_JJ mice_NNS were_VBD evaluated_VBN ._SENT For_IN the_DT MMV_NP ELISA_NP ,_, the_DT median_JJ absorbance_NN value_NN for_IN sera_NN from_IN MMV-infected_JJ mice_NNS was_VBD statistically_RB higher_JJR than_IN the_DT median_JJ absorbance_NN values_NNS for_IN sera_NN from_IN mice_NNS infected_VBN with_IN MPV_NN or_CC sera_NN from_IN parvovirus-free_JJ mice_NNS (_( P_NN <_SYM 0.01_CD )_) ._SENT For_IN the_DT MPV_NP ELISA_NP ,_, the_DT median_JJ absorbance_NN value_NN for_IN sera_NN from_IN MPV-infected_JJ mice_NNS was_VBD significantly_RB higher_JJR than_IN the_DT median_JJ absorbance_NN values_NNS for_IN sera_NN from_IN mice_NNS infected_VBN with_IN MMV_NP or_CC sera_NN from_IN parvovirus-free_JJ mice_NNS (_( P_NN <_SYM 0.01_CD )_) ._SENT Prevalence_NN of_IN MMV_NP and_CC MPV_NP infections_NNS in_IN research_NN mice_NNS ._SENT |_SYM In_IN addition_NN to_TO evaluating_VBG sera_NN from_IN experimentally_RB infected_JJ mice_NNS ,_, we_PP also_RB evaluated_VBD all_DT mouse_NN serum_NN samples_NNS that_WDT were_VBD submitted_VBN for_IN routine_JJ serologic_JJ evaluation_NN over_IN a_DT 4-week-period_JJ to_TO the_DT University_NP of_IN Missouri_NP Research_NP Animal_NP Diagnostic_NP Laboratory_NP (_( Columbia_NP ,_, Mo._NP )_) ._SENT These_DT sera_NN were_VBD from_IN 83_CD research_NN institutions_NNS throughout_IN the_DT United_NP States_NPS and_CC Canada_NP and_CC were_VBD obtained_VBN from_IN a_DT variety_NN of_IN immunocompetent_JJ mouse_NN strains_NNS and_CC stocks_NNS ._SENT Of_IN 2,473_CD mouse_NN serum_NN samples_NNS tested_VBD ,_, 205_CD serum_NN samples_NNS (_( 8.3_CD %_NN )_) were_VBD positive_JJ for_IN MPV_NP by_IN ELISA_NP ,_, 38_CD serum_NN samples_NNS (_( 1.5_CD %_NN )_) were_VBD positive_JJ for_IN MMV_NP by_IN ELISA_NP ,_, and_CC 32_CD serum_NN samples_NNS (_( 1.3_CD %_NN )_) were_VBD positive_JJ for_IN both_DT MMV_NP and_CC MPV_NP by_IN ELISA_NP ._SENT Seventeen_CD institutions_NNS had_VBD sera_NN positive_JJ for_IN MPV_NP ,_, three_CD institutions_NNS had_VBD sera_NN positive_JJ for_IN MMV_NP ,_, and_CC five_CD institutions_NNS had_VBD sera_NN positive_JJ for_IN both_DT agents_NNS ._SENT A_DT group_NN of_IN 22_CD mice_NNS that_WDT were_VBD serologically_RB positive_JJ for_IN MMV_NP and_CC MPV_NP by_IN ELISA_NP were_VBD also_RB evaluated_VBN for_IN the_DT presence_NN of_IN MMV_NP and_CC MPV_NP DNA_NP by_IN PCR_NP analysis_NN of_IN the_DT mesenteric_JJ lymph_NN nodes_NNS ._SENT Of_IN these_DT 22_CD mice_NNS ,_, 19_CD were_VBD positive_JJ for_IN MMV_NP and_CC MPV_NP by_IN PCR_NP ._SENT Collectively_RB ,_, these_DT data_NNS suggest_VBP that_IN MPV_NP and_CC MMV_NP infections_NNS are_VBP present_JJ in_IN research_NN mouse_NN colonies_NNS ,_, MPV_NN infections_NNS are_VBP more_RBR prevalent_JJ than_IN MMV_NP infections_NNS ,_, and_CC dual_JJ infections_NNS with_IN MPV_NP and_CC MMV_NP occur_VBP in_IN some_DT mice_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Transmission_NP electron_NN micrographs_NNS of_IN negative_JJ stained_VBN preparations_NNS of_IN MPV_NP VLPs_NP produced_VBD from_IN baculovirus-expressed_JJ MPV_NP rVP2_NN protein_NN (_( A_NP )_) and_CC MMV_NP VLPs_NP produced_VBD from_IN baculovirus-expressed_JJ MMV_NP rVP2_NN protein_NN (_( B_NP )_) ._SENT Transmission_NP electron_NN micrographs_NNS of_IN negative_JJ stained_VBN preparations_NNS of_IN MPV_NP VLPs_NP produced_VBD from_IN baculovirus-expressed_JJ MPV_NP rVP2_NN protein_NN (_( A_NP )_) and_CC MMV_NP VLPs_NP produced_VBD from_IN baculovirus-expressed_JJ MMV_NP rVP2_NN protein_NN (_( B_NP )_) ._SENT The_DT VLPs_NP were_VBD purified_VBN by_IN CsCl_NP gradient_JJ ultracentrifugation_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Western_JJ blot_NN analysis_NN of_IN MPV_NP rVP2_NP VLPs_NP or_CC MMV_NP rVP2_NP VLPs_NP separated_VBD by_IN SDS-PAGE_NP ._SENT Western_JJ blot_NN analysis_NN of_IN MPV_NP rVP2_NP VLPs_NP or_CC MMV_NP rVP2_NP VLPs_NP separated_VBD by_IN SDS-PAGE_NP ._SENT The_DT blot_NN was_VBD probed_VBN with_IN sera_NN from_IN MPV-infected_JJ mice_NNS (_( lanes_NNS 1_CD to_TO 5_CD )_) ,_, MMV-infected_JJ mice_NNS (_( lanes_NNS 6_CD to_TO 10_CD )_) ,_, and_CC uninfected_JJ mice_NNS (_( lanes_NNS 11_CD and_CC 12_CD )_) ._SENT Each_DT lane_NN contains_VBZ 5_CD mug_NN of_IN protein_NN ;_: test_NN sera_NN were_VBD run_VBN at_IN a_DT 1:200_CD dilution_NN ._SENT The_DT positions_NNS of_IN the_DT MPV_NP rVP2_NN and_CC the_DT MMV_NP rVP2_NN are_VBP indicated_VBN by_IN arrows_NNS on_IN the_DT left_NN and_CC right_NN ,_, respectively_RB ._SENT The_DT positions_NNS of_IN the_DT molecular_JJ mass_NN standards_NNS are_VBP indicated_VBN on_IN the_DT left_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Serum_NP antibody_NN responses_NNS of_IN mice_NNS experimentally_RB infected_VBN with_IN MMV_NP or_CC MPV_NP or_CC of_IN uninfected_JJ mice_NNS tested_VBN by_IN MMV_NP ELISA_NP (_( A_NP )_) or_CC MPV_NP ELISA_NP (_( B_NP )_) ._SENT Serum_NP antibody_NN responses_NNS of_IN mice_NNS experimentally_RB infected_VBN with_IN MMV_NP or_CC MPV_NP or_CC of_IN uninfected_JJ mice_NNS tested_VBN by_IN MMV_NP ELISA_NP (_( A_NP )_) or_CC MPV_NP ELISA_NP (_( B_NP )_) ._SENT The_DT datum_NN points_NNS are_VBP presented_VBN as_IN box_NN plots_NNS ;_: for_IN each_DT experimental_JJ group_NN the_DT lower_JJR boundary_NN of_IN the_DT box_NN indicates_VBZ the_DT 25th_JJ percentile_NN ,_, the_DT upper_JJ boundary_NN of_IN the_DT box_NN indicates_VBZ the_DT 75th_JJ percentile_NN ,_, and_CC the_DT line_NN within_IN the_DT box_NN marks_VBZ the_DT median_JJ value_NN ._SENT The_DT line_NN below_IN the_DT box_NN marks_VBZ the_DT 10th_JJ percentile_NN ,_, the_DT line_NN above_IN the_DT box_NN marks_VBZ the_DT 90th_NN percentile_NN ,_, and_CC datum_NN points_NNS outside_IN this_DT range_NN are_VBP indicated_VBN (_( *_SYM )_) ._SENT *_SYM ,_, P_NN <_SYM 0.01_CD compared_VBN to_TO each_DT other_JJ experimental_JJ group_NN ._SENT TABLE_NN 1_CD |_SYM Comparison_NN of_IN serologic_JJ test_NN results_NNS for_IN uninfected_JJ mice_NNS and_CC mice_NNS experimentally_RB infected_VBN with_IN MPV_NP or_CC MMV_NP In_IN this_DT report_NN ,_, we_PP describe_VBP the_DT development_NN of_IN ELISAs_NNS that_WDT detect_VBP anti-MMV_NP or_CC anti-MPV_NP antibodies_NNS in_IN the_DT sera_NN of_IN parvovirus-infected_JJ mice_NNS ._SENT The_DT MMV_NP ELISA_NP and_CC the_DT MPV_NP ELISA_NP displayed_VBD high_JJ sensitivities_NNS and_CC high_JJ specificities_NNS for_IN the_DT detection_NN of_IN species-specific_JJ parvovirus_NN antibodies_NNS in_IN MMV-_NP and_CC MPV-infected_JJ mice_NNS ,_, and_CC each_DT ELISA_NP had_VBD high_JJ positive_JJ and_CC negative_JJ predictive_JJ values_NNS ._SENT These_DT assays_NNS are_VBP ideally_RB suited_VBN for_IN use_NN as_IN primary_JJ serologic_JJ tests_NNS to_TO screen_VB mouse_NN colonies_NNS for_IN MMV_NP and_CC MPV_NP infections_NNS because_IN the_DT assays_NNS were_VBD highly_RB accurate_JJ and_CC because_IN ELISAs_NP are_VBP readily_RB automated_VBN ,_, making_VBG it_PP possible_JJ to_TO test_VB large_JJ numbers_NNS of_IN samples_NNS quickly_RB and_CC at_IN relatively_RB little_JJ expense_NN ._SENT In_IN addition_NN ,_, large_JJ quantities_NNS of_IN the_DT MMV_NP rVP2_NN and_CC the_DT MPV_NP rVP2_NN antigens_NNS used_VBN in_IN these_DT assays_NNS were_VBD readily_RB produced_VBN with_IN the_DT baculovirus_NN expression_NN system_NN ,_, providing_VBG ample_JJ antigens_NNS for_IN high-volume_JJ testing_NN ._SENT This_DT is_VBZ particularly_RB significant_JJ for_IN MPV_NP because_IN it_PP is_VBZ difficult_JJ and_CC expensive_JJ to_TO produce_VB large_JJ quantities_NNS of_IN MPV-specific_NP ELISA_NP antigens_NNS in_IN vitro_NN from_IN MPV-infected_JJ cells_NNS ._SENT The_DT MMV_NP and_CC MPV_NP ELISAs_NP performed_VBD with_IN high_JJ sensitivities_NNS in_IN detecting_VBG MMV_NP and_CC MPV_NP infections_NNS in_IN mice_NNS ,_, respectively_RB ,_, and_CC these_DT two_CD assays_NNS were_VBD much_RB more_RBR sensitive_JJ in_IN detecting_VBG parvovirus_NN infections_NNS in_IN mice_NNS than_IN a_DT generic_JJ parvovirus_NN ELISA_NN that_WDT uses_VBZ a_DT recombinant_JJ nonstructural_JJ protein_NN (_( rNS1_JJ )_) of_IN MMV_NP as_IN antigen_NN ._SENT This_DT is_VBZ consistent_JJ with_IN previous_JJ work_NN that_WDT shows_VBZ that_IN mice_NNS experimentally_RB inoculated_VBN with_IN MPV_NP ,_, especially_RB mice_NNS infected_VBN after_IN 12_CD weeks_NNS of_IN age_NN ,_, develop_VB anticapsid_JJ antibodies_NNS more_RBR so_RB than_IN anti-NS1_JJ antibodies_NNS ._SENT The_DT VP2_NP protein_NN is_VBZ the_DT major_JJ capsid_NN protein_NN of_IN the_DT parvovirus_NN virion_NN and_CC can_MD be_VB presented_VBN to_TO the_DT immune_JJ system_NN upon_IN exposure_NN to_TO the_DT virus_NN or_CC during_IN viral_JJ replication_NN ._SENT However_RB ,_, nonstructural_JJ proteins_NNS ,_, including_VBG NS1_NP ,_, are_VBP not_RB present_JJ in_IN the_DT parvovirus_NN virion_NN and_CC are_VBP produced_VBN more_RBR transiently_RB upon_IN infection_NN ._SENT Thus_RB ,_, an_DT undetectable_JJ anti-NS1_JJ humoral_JJ immune_JJ response_NN could_MD result_VB from_IN a_DT nonproductive_JJ parvovirus_NN infection_NN or_CC from_IN a_DT productive_JJ infection_NN that_WDT produces_VBZ an_DT insufficient_JJ amount_NN of_IN NS1_NP to_TO induce_VB an_DT immune_JJ response_NN ._SENT The_DT MMV_NP and_CC MPV_NP ELISAs_NP also_RB performed_VBD with_IN high_JJ specificities_NNS in_IN detecting_VBG MMV_NP and_CC MPV_NP infections_NNS in_IN mice_NNS ,_, respectively_RB ._SENT Previously_RB described_VBN ELISAs_NNS that_WDT use_VBP whole-virus_NN preparations_NNS of_IN MMV_NP or_CC rNS1_JJ proteins_NNS as_IN antigens_NNS are_VBP not_RB specific_JJ for_IN the_DT identification_NN of_IN MMV-_NP and_CC MPV-infected_JJ mice_NNS and_CC require_VB the_DT use_NN of_IN secondary_JJ testing_NN with_IN MMV-_NP or_CC MPV-specific_NP HAI_NP assays_VBZ to_TO elucidate_VB the_DT true_JJ infection_NN status_NN of_IN the_DT animal_NN ._SENT Thus_RB ,_, the_DT high_JJ specificities_NNS of_IN the_DT newly_RB developed_VBN MMV_NP and_CC MPV_NP ELISAs_NP eliminate_VB the_DT need_NN for_IN secondary_JJ testing_NN by_IN the_DT HAI_NP assay_NN ._SENT An_DT interesting_JJ feature_NN of_IN the_DT baculovirus-expressed_JJ MMV_NP and_CC MPV_NP rVP2_NN proteins_NNS was_VBD that_IN they_PP self-assembled_VBD into_IN VLPs_NP that_WDT were_VBD morphologically_RB similar_JJ to_TO empty_VB parvovirus_NN capsids_NNS ._SENT Self-assembly_NN of_IN baculovirus-expressed_JJ recombinant_JJ parvovirus_NN VP2_NN proteins_NNS has_VBZ been_VBN reported_VBN for_IN many_JJ parvoviruses_NNS including_VBG MMV_NP ;_: however_RB ,_, this_DT is_VBZ the_DT first_JJ report_NN of_IN self-assembly_NN of_IN MPV_NN rVP2_NN into_IN VLPs_NP ._SENT MMV_NP rVP2_NP and_CC MPV_NP rVP2_NN were_VBD expressed_VBN as_IN fusion_NN proteins_NNS that_WDT contained_VBD an_DT N-terminal_JJ polyhistidine_NN tag_NN with_IN the_DT intent_NN of_IN purifying_VBG these_DT proteins_NNS by_IN metal-affinity_NN chromatography_NN ._SENT In_IN preliminary_JJ experiments_NNS ,_, MMV_NP rVP2_NP and_CC MPV_NP rVP2_NN could_MD not_RB be_VB successfully_RB purified_VBN by_IN affinity_NN chromatography_NN (_( data_NNS not_RB shown_VBN )_) ._SENT However_RB ,_, this_DT proved_VBN to_TO be_VB unnecessary_JJ because_IN the_DT semipurified_JJ preparation_NN of_IN MMV_NP rVP2_NN was_VBD highly_RB immunoreactive_JJ and_CC therefore_RB required_VBN no_DT further_JJR purification_NN ._SENT While_IN the_DT semipurified_JJ preparation_NN of_IN MPV_NP was_VBD weakly_RB immunoreactive_JJ ,_, highly_RB immunoreactive_JJ MPV_NN rVP2_NN in_IN the_DT form_NN of_IN MPV_NP VLPs_NP was_VBD easily_RB purified_VBN by_IN CsCl_NP ultracentrifugation_NN ._SENT The_DT N-terminal_JJ polyhistidine_NN tag_NN and_CC leader_NN sequences_NNS added_VBD an_DT estimated_VBN 3.6_CD kDa_NN to_TO each_DT rVP2_NN ._SENT While_IN the_DT leader_NN peptides_NNS did_VBD not_RB alter_VB the_DT ability_NN of_IN the_DT rVP2_JJ proteins_NNS to_TO assemble_VB into_IN VLPs_NP ,_, they_PP may_MD have_VB caused_VBN a_DT slight_JJ decrease_NN in_IN the_DT densities_NNS of_IN the_DT VLPs_NP (_( 1.31_CD g/cm3_NN of_IN CsCl_NP )_) compared_VBD to_TO previously_RB reported_VBN densities_NNS of_IN MMV_NP VLPs_NP and_CC empty_JJ parvovirus_NN capsids_NNS (_( 1.32_CD g/cm3_NN of_IN CsCl_NP )_) ._SENT The_DT formation_NN of_IN VLPs_NP by_IN the_DT MMV_NP and_CC MPV_NP rVP2_JJ proteins_NNS may_MD have_VB contributed_VBN to_TO the_DT high_JJ sensitivities_NNS of_IN the_DT MMV_NP and_CC MPV_NP ELISAs_NP ._SENT Interestingly_RB ,_, the_DT MMV_NP rVP2_NN protein_NN that_WDT was_VBD subjected_VBN to_TO Western_JJ blotting_VBG reacted_VBD strongly_RB with_IN only_RB four_CD of_IN five_CD MMV-positive_JJ serum_NN samples_NNS ._SENT The_DT one_CD MMV-positive_JJ serum_NN sample_NN that_WDT reacted_VBD weakly_RB with_IN MMV_NP rVP2_NN by_IN Western_NP blotting_VBG was_VBD strongly_RB reactive_JJ with_IN MMV_NP rVP2_NN by_IN ELISA_NP ._SENT It_PP is_VBZ possible_JJ that_IN conformational_JJ epitopes_NNS present_JJ on_IN the_DT exterior_NN of_IN the_DT MMV_NP VLPs_NP were_VBD not_RB present_JJ when_WRB MMV_NP rVP2_NN was_VBD disrupted_VBN or_CC denatured_VBN for_IN Western_JJ blot_NN analysis_NN ._SENT Our_PP$ data_NNS also_RB suggest_VBP that_DT formation_NN of_IN MMV_NP and_CC MPV_NP VLPs_NP likely_RB enhanced_VBD the_DT specificities_NNS of_IN the_DT MMV_NP and_CC MPV_NP ELISAs_NP over_IN those_DT which_WDT would_MD be_VB attained_VBN with_IN unassembled_JJ MMV_NP rVP2_NN or_CC MPV_NN rVP2_NN proteins_NNS as_IN antigens_NNS ._SENT Sera_NN from_IN two_CD MPV-infected_JJ mice_NNS strongly_RB cross-reacted_VBN with_IN MMV_NP rVP2_JJ proteins_NNS on_IN Western_JJ blots_NNS ._SENT These_DT sera_NN did_VBD not_RB cross-react_NN with_IN MMV_NP rVP2_NN in_IN an_DT ELISA_NP format_NN ._SENT In_IN addition_NN ,_, two_CD serum_NN samples_NNS from_IN MMV-infected_JJ mice_NNS displayed_VBD weak_JJ cross-reactivity_NN with_IN MPV_NN rVP2_NN ._SENT These_DT two_CD serum_NN samples_NNS were_VBD not_RB cross-reactive_JJ with_IN the_DT MPV_NP rVP2_NN protein_NN in_IN an_DT ELISA_NP format_NN ._SENT A_DT possible_JJ explanation_NN for_IN these_DT observations_NNS is_VBZ that_IN in_IN the_DT ELISA_NP format_NN ,_, the_DT MMV_NP rVP2_NN and_CC MPV_NN rVP2_NN VLPs_NNS behave_VBP antigenically_RB like_VB whole_JJ virions_NNS and_CC anticapsid_JJ antibodies_NNS are_VBP able_JJ to_TO associate_VB only_RB with_IN antigenic_JJ epitopes_NNS present_JJ on_IN the_DT exterior_NN of_IN the_DT VLPs_NP ._SENT However_RB ,_, when_WRB the_DT VLPs_NNS are_VBP subjected_VBN to_TO SDS-PAGE_NP and_CC Western_JJ blotting_VBG ,_, the_DT VLPs_NNS are_VBP disrupted_VBN and_CC the_DT proteins_NNS are_VBP denatured_VBN ,_, possibly_RB exposing_VBG cross-reactive_JJ epitopes_NNS ._SENT The_DT MMV_NP and_CC MPV_NP ELISAs_NP were_VBD used_VBN to_TO survey_VB sera_NN obtained_VBN from_IN numerous_JJ mo_NN 